Emmes Announces FDA Approved a Prescription-Only Device Used to Estimate the Weight of Infants Who Are Up to 90 days of Age

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

The Mercy babyTAPE is a tape-measure-like device that permits health care professionals to estimate the bodyweight of preterm and full-term infants when a scale may not be available or practical to use. Accurately estimating pediatric patient weight is important for drug dosing, resuscitation interventions, and nutritional assessments. This easy-to-produce device could be especially useful in emergency or resource-constrained situations such as remote or rural areas, and in developing countries.

The Mercy babyTAPE was developed under the Best Pharmaceuticals for Children Act, which mandates the National Institutes of Health (NIH) to prioritize therapeutic areas in critical need of pediatric-specific treatment information, sponsor pediatric clinical trials, and submit the data for review by the U.S. Food and Drug Administration (FDA) for action on affected products.

Emmes coordinated operations and analyzed the data from the NIH-funded studies for the original Mercy TAPE devices, which are used in children ages 2-16 years.  These were the first weight estimation devices developed under the BPCA program and the first weight estimation devices to be cleared by the FDA.  The Mercy babyTAPE now brings the same weight estimation process to infants.

All were developed by Dr. Susan M. Abdel-Rahman at The Children’s Mercy Hospital of Kansas City, Missouri.  According to Dr. Abdel-Rahman, “We now have a suite of low-cost, easy-to-use tools that take the guesswork out of estimating weight, one of the most important vital signs in a child.  Combined, the Mercy TAPE and babyTAPE permit weight estimation from birth through adolescence in settings where this information is critical for delivering the best medical care possible.”

Dr. Anne Lindblad, president, and chief executive officer of Emmes, added, “The development of the TAPE devices is a wonderful example of collaboration between government agencies, researchers and industry.  It’s an honor for Emmes to partner with an outstanding researcher like Dr. Abdel-Rahman.”

 

spot_img

DON'T MISS

Related Articles